# EDGAR Filing Document

**Accession Number:** 0000749647
**File Stem:** 0001493152-26-012161
**Filing Date:** 2026-3
**Character Count:** 4628
**Document Hash:** d009af9642996a286581dab5cc6d76d5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-012161.hdr.sgml**: 20260323

**ACCESSION NUMBER**: 0001493152-26-012161

**CONFORMED SUBMISSION TYPE**: 424B5

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260323

**DATE AS OF CHANGE**: 20260323

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Imunon, Inc.
- **CENTRAL INDEX KEY:** 0000749647
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 521256615
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B5
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-279425
- **FILM NUMBER:** 26782402

**BUSINESS ADDRESS:**
- **STREET 1:** 997 LENOX DRIVE
- **STREET 2:** SUITE 100
- **CITY:** LAWRENCEVILLE
- **STATE:** NJ
- **ZIP:** 08648
- **BUSINESS PHONE:** (609) 896-9100

**MAIL ADDRESS:**
- **STREET 1:** 997 LENOX DRIVE
- **STREET 2:** SUITE 100
- **CITY:** LAWRENCEVILLE
- **STATE:** NJ
- **ZIP:** 08648

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Celsion CORP
- **DATE OF NAME CHANGE:** 20071121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CELSION CORP
- **DATE OF NAME CHANGE:** 19980515

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHEUNG LABORATORIES INC
- **DATE OF NAME CHANGE:** 19920703

**Filed Pursuant to Rule 424(b)(5)**

**Registration No. 333-279425**

**PROSPECTUS SUPPLEMENT NO. 3**

(to Prospectus dated May 22, 2024,

Prospectus Supplement dated September 3, 2024, and

Prospectus Supplement dated July 22, 2025)

![](form424b5_001.jpg)

**IMUNON, INC.**

**Up to $17,000,000 of Common Stock**

This prospectus supplement amends and supplements the information in the prospectus supplement, dated September 3, 2024, as amended and supplemented by the prospectus supplement dated July 22, 2025 (as amended and supplemented, the "ATM Prospectus Supplement"), to the accompanying base prospectus, dated May 22, 2024 (the "Base Prospectus" and, collectively with the ATM Prospectus Supplement, the "Prospectus") filed as part of our registration statement on Form S-3 (File No. 333-279425) (the "Registration Statement"), relating to the offer, issuance and sale of shares of our common stock, par value $0.01 per share ("Common Stock"), from time to time pursuant to the terms of an At the Market Offering Agreement, dated as of May 25, 2022, as amended by Amendment No. 1 to At the Market Offering Agreement, dated as of May 15, 2024 (as amended, the "Sales Agreement"), by and between us and H.C. Wainwright & Co., LLC, as sales agent or principal ("Wainwright" or the "sales agent"). Through the date hereof, we have sold an aggregate of $4,797,848 of shares of our Common Stock through the sales agent under the Sales Agreement. This prospectus supplement should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus, and any future amendments or supplements thereto.

We are filing this prospectus supplement to amend and supplement the Prospectus to increase the aggregate amount we intend to sell pursuant to the Sales Agreement. As of the date of this prospectus supplement, we are offering up to an aggregate of $17,000,000 of our Common Stock for sale under the Sales Agreement, consisting of $10,000,000 that was previously authorized pursuant to the ATM Prospectus Supplement and an additional $7,000,000 pursuant to this prospectus supplement.

Our Common Stock is listed on The Nasdaq Stock Market LLC under the symbol "IMNN." On March 19, 2026, the last reported sale price for our Common Stock on Nasdaq was $2.95 per share.

The validity of the shares being offered hereby will be passed upon by Thompson Hine LLP.

**Investing in our securities involves a high degree of risk. Before making an investment decision, please read "Risk Factors" beginning on page S-3 of the ATM Prospectus Supplement dated September 3, 2024 and the other documents and information contained or incorporated by reference in this prospectus supplement and the ATM Prospectus Supplement.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.** 

**H.C. Wainwright & Co.**

**The date of this prospectus supplement is March 23, 2026**